Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An adverse outcome pathway for cigarette smoke-mediated oxidative stress in plaque formation.

Frontiers in toxicology·2025
Same author

Application of ToxTracker for the toxicological assessment of tobacco and nicotine delivery products.

Toxicology letters·2022
Same author

Engineering multi-layered tissue constructs using acoustic levitation.

Scientific reports·2019
Same author

Hydration and nanomechanical changes in collagen fibrils bearing advanced glycation end-products.

Biomedical optics express·2019
Same author

Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis.

eLife·2018
Same author

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.

Oncotarget·2017

Related Experiment Video

Updated: May 27, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Improving RDS treatment with current drugs.

David E Smart1, Marc B Princivalle

  • 1Human Development and Health, School of Medicine, University of Southampton, Southampton, UK. d.smart@soton.ac.uk

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
|November 26, 2011
PubMed
Summary

Respiratory distress syndrome, a leading cause of infant mortality, may be better managed. Combining corticosteroids with a single dose of a beta-agonist before delivery could improve fetal lung maturation.

More Related Videos

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

Related Experiment Videos

Last Updated: May 27, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

Area of Science:

  • Neonatal medicine
  • Fetal development
  • Respiratory physiology

Background:

  • Respiratory distress syndrome (RDS) is a major cause of infant mortality in the USA, often linked to underdeveloped fetal lungs.
  • Current treatments like corticosteroids have limitations, including a 24-hour latency period and minimal impact on surfactant production.

Purpose of the Study:

  • To explore synergistic approaches for accelerating fetal lung maturation and improving respiratory adaptation at birth.
  • To re-evaluate the potential of beta-agonists in conjunction with existing therapies for preventing RDS.

Main Methods:

  • Review of in vivo evidence on the role of vaginal delivery in final fetal lung preparation.
  • Analysis of the combined effects of natural maturation, steroidal agents, and beta-agonists on lung adaptation.
  • Consideration of oxytocin and corticosteroids for vulnerable pregnancies.

Main Results:

  • Vaginal delivery naturally triggers rapid fetal lung maturation, enhancing fluid re-absorption and surfactant production.
  • A single pre-delivery dose of a beta-agonist may optimize lung adaptation, potentially overcoming previous therapeutic limitations.
  • Combining corticosteroids with beta-agonists could offer a synergistic approach to RDS prevention.

Conclusions:

  • Optimizing fetal lung adaptation through a combination of therapies, including beta-agonists, presents a promising strategy for reducing RDS.
  • Addressing challenges posed by increasing premature births and cesarean sections may involve refining current treatment protocols for RDS.